Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18469383 | 0.82 | SIGMAR1 (0.49) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL10130332 | 0.82 | SIGMAR1 (0.53) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL28210210 | 0.77 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL129446 | 0.77 | SIGMAR1 (0.51) | SIGMAR1TSHR | |
| SCHEMBL30966769 | 0.77 | SIGMAR1 (0.51) | SIGMAR1TSHR | |
| SCHEMBL17485887 | 0.77 | SIGMAR1 (0.51) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL8765716 | 0.77 | SIGMAR1 (0.47) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL13142775 | 0.76 | SIGMAR1 (0.50) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL1529253 | 0.75 | SIGMAR1 (0.50) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL14236879 | 0.75 | SIGMAR1 (0.46) | SIGMAR1TP53CYP2D6TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | SIGMAR1 1869/4885TP53 2081/4885CYP2D6 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.